Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit - Novo Nordisk (NYSE:NVO)

Strive alleges Eli Lilly and Novo Nordisk coordinated to limit access to compounded GLP-1 drugs, impacting providers and patients in the U.S. healthcare system.

  • On Jan. 14, 2026 Strive Compounding Pharmacy filed a federal antitrust lawsuit accusing Eli Lilly & Co. and Novo Nordisk of suppressing competition and limiting access to compounded GLP-1 medicines.
  • Because compounding fills clinical gaps, compounding pharmacies provide tailored medications when FDA-approved drugs don't fit or face shortages, and Strive alleges defendants' conduct threatens fair competition.
  • Strive posted the full complaint online and is represented by BakerHostetler in Strive Specialties Inc. v. Eli Lilly & Co. et al., while CEO Nate Hill framed the case as a fight for patient access and medical judgment.
  • Strive says the filing aims to protect a lawful compounding industry millions of Americans rely on, warning that without compounding, patient access can vanish and prices can skyrocket.
  • Positioning itself as a defender of personalized care, Strive Compounding Pharmacy highlights telehealth collaborations and emphasizes fair competition's role in protecting medical judgment and patient access.
Insights by Ground AI

27 Articles

sherwood.newssherwood.news
Reposted by
BizTocBizToc
Lean Left

Lawsuit alleges Lilly, Novo locked up telehealth to kill compounded GLP-1s

Novo Nordisk CEO Mike Doustdar estimated that around 1.5 million US patients are using compounded versions of the company’s drugs....

Read Full Article
BenzingaBenzinga
Center

Novo Nordisk Stock Dips As Company Faces GLP-1 Antitrust Lawsuit - Novo Nordisk (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) shares are trading lower on Thursday after the company was hit with a lawsuit from compounding pharmacy Strive Specialties.

·New York, United States
Read Full Article
STATSTAT
Center

Pharmacy compounder files antitrust lawsuit against Eli Lilly and Novo Nordisk

The lawsuit comes as the obesity drug market has taken on the aura of a modern-day gold rush with sales forecast to each $95 billion by 2030

·Boston, United States
Read Full Article
Hanford SentinelHanford Sentinel
+19 Reposted by 19 other sources
Center

Strive Compounding Pharmacy Files Landmark Antitrust Lawsuit Against Eli Lilly and Novo Nordisk

Lawsuit alleges anti-competitive conduct designed to suppress lawful compounding pharmaceuticals and limit patient choice

Read Full Article
USA HeraldUSA Herald

Compounding Pharmacy Accuses Eli Lilly, Novo Nordisk of Blocking GLP-1 Competition

An Arizona-based compounding pharmacy has filed what it calls a landmark antitrust lawsuit accusing Eli Lilly & Co. and Novo Nordisk of using their

Read Full Article
GeneOnline NewsGeneOnline News

Compounding Pharmacy Sues Eli Lilly and Novo Nordisk Over Alleged Anticompetitive Practices in Obesity Drug Market

A compounding pharmacy has initiated legal action again […] The post Compounding Pharmacy Sues Eli Lilly and Novo Nordisk Over Alleged Anticompetitive Practices in Obesity Drug Market first appeared on GeneOnline News. The post Compounding Pharmacy Sues Eli Lilly and Novo Nordisk Over Alleged Anticompetitive Practices in Obesity Drug Market appeared first on GeneOnline News.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 83% of the sources are Center
83% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

PR Newswire broke the news in United States on Wednesday, January 14, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Eli Lilly icon

Eli Lilly

GLP-1 icon

GLP-1

India icon

India

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal